|
|
|
03.07.25 - 08:01
|
Hansa Biopharma to host Q2 2025 interim results conference call (Cision)
|
|
|
Lund, Sweden, 3 July 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - June 2025 on 17 July 2025. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM ET. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Hitto Kaufmann, CR&DO, and Maria Törnsén COO and President U.S. The call will include a review of the interim results and a business and pipeline update. It will be held in English.
Slides used in the presentation will be made available on the company...
|
|
|
|
|
30.06.25 - 07:01
|
Hansa Biopharma: Increase in number of shares and votes (Cision)
|
|
|
Lund, Sweden June 30, 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announces that Hansa's registered share capital and number of shares and votes have increased through (i) the issue of 10,550,000 new ordinary shares resolved on 19 June 2025 and registered with the Swedish Companies Registration Office on 24 June 2025, whereby the number of shares and votes increased with 10,550,000 and the share capital increased with SEK 10,550,000 and (ii) the set-off issue of 6,398,981 shares resolved upon on 19 June 2025 and registered with the Swedish Companies Registration Office on...
|
|
|
25.06.25 - 16:01
|
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) (Cision)
|
|
|
Lund, Sweden, June 25, 2025. Hansa Biopharma AB (publ), “Hansa” (Nasdaq Stockholm: HNSA), has today on June 25, 2025 held its Annual General Meeting. The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The Annual General Meeting of Hansa passed the following resolutions.
Resolution regarding the adoption of the income statement and the balance sheet as well as consolidated income statement and consolidated balance sheet, appropriation of result and discharge from...
|
|
|
11.06.25 - 09:06
|
Hansa Biopharma to attend BIO International Convention (PR Newswire)
|
|
|
LUND, Sweden, June 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that Hansa's CEO Renée Aguiar-Lucander will speak at the BIO International Convention at the Boston Convention & Exhibition Center, Boston, MA, June 16-19. Aguiar-Lucander......
|
|
|
|
|
26.05.25 - 18:42
|
Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency (Cision)
|
|
|
Lund, Sweden, 26 May 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that it plans to restructure the organization to optimize resource allocation and improve operational efficiency. The planned restructuring would result in an approximately 20% reduction in the current workforce and will result in projected annual savings of 40-50 MSEK in annual savings. The restructuring is subject to negotiation with relevant trade unions.
Renée Aguiar-Lucander, CEO, Hansa Biopharma said: “This planned restructuring is a strategic decision to optimize resources and improve...
|
|
|
26.05.25 - 07:01
|
Notice to Annual General Meeting in Hansa Biopharma AB (publ) (Cision)
|
|
|
Lund, Sweden May 26, 2025, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gives notice to Annual General Meeting to be held on Wednesday June 25, 2025 at 14:30 CEST, Elite Hotel Ideon, Scheelevägen 27, SE-223 63 Lund. Registration starts at 14:00 CEST.
Right to participate in the Annual General Meeting and notice of participation
Participation in the Annual General Meeting at the venue
A shareholder who wishes to participate in the Annual General Meeting at the venue in person or represented by a proxy must (i) be recorded as a...
|
|
|
|
|
|
|
|
|
|
|
|
|
24.04.25 - 07:01
|
Hansa Biopharma appoints new Chief Executive Officer (Cision)
|
|
|
Lund, Sweden, 24 April 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately. Søren Tulstrup will be stepping down from his position by mutual agreement as CEO after seven years of dedicated service to the Company.
“On behalf of the Board of Directors, I would like to extend our gratitude to Søren for his leadership and significant contribution to the company during his tenure. Under his guidance, Hansa has evolved from a clinical-stage company into a commercial-stage...
|
|
|
03.04.25 - 08:06
|
Hansa Biopharma to host Q1 2025 interim results conference call (Cision)
|
|
|
Lund, Sweden, 3 April, 2025. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January - March 2025 on 24 April, 2025. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00AM ET. The event will be hosted by Søren Tulstrup, President and CEO, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim results and a business and pipeline update. It will be held in English.
Slides used in the presentation will be made available on the company website at the following...
|
|
|
25.03.25 - 09:00
|
Hansa Biopharma to attend Van Lanschot Kempen Life Sciences Conference (Cision)
|
|
|
Lund, Sweden, 25 March 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend Van Lanschot Kempen Life Sciences Conference in Amsterdam, NL, on 2-3 April. Hansa management will be available for meetings at the conference. If you are interested in meeting with the management team, please contact Hansa Biopharma at ir@hansabiopharma.com.
To learn more about Hansa Biopharma see the latest Corporate Presentation here. (https://www.hansabiopharma.com/investors/presentations-events/) The Company's year-end financial report can be found here (https://www....
|
|
|
|
|
|
|
04.03.25 - 08:01
|
Hansa Biopharma to attend Leerink Partners Global Healthcare Conference (Cision)
|
|
|
Lund, Sweden, 4 March 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced it will attend Leerink Partners Global Healthcare Conference on 10-12 March in Miami, FL. Hansa management will be available for meetings at the conference. If you are interested in meeting with the management team, please contact Hansa Biopharma at ir@hansabiopharma.com.
To learn more about Hansa Biopharma see the latest Corporate Presentation here. (https://www.hansabiopharma.com/investors/presentations-events/) The latest investor presentation can be viewed here (https://www....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
